Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
Watch Beam Therapeutics' latest callBeam Therapeutics (NASDAQ:BEAM) Q4 2025 Earnings Call · Replay · Feb 24Read the transcript of Beam Therapeutics (NASDAQ:BEAM) Q4 2025 Earnings CallStory so far
- Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
- Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
- Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
Earlier from Beam Therapeutics
- Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
- Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress
- Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference
- Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Later from Beam Therapeutics
- Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
- Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
- Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
- Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Follow Beam Therapeutics into a list and get an email when it puts out news.
Follow Beam Therapeutics